论文部分内容阅读
目的研究MMP-2、MMP-9(matrixmetalloproteinase,基质金属蛋白酶)、Cathepsin-D(组织蛋白酶D)在淋巴结阴性乳腺癌中的表达与预后的关系。方法用免疫组织化学ABC法检测270例淋巴结阴性乳腺癌患者肿瘤组织中MMP-2、MMP-9、Cathepsin-D的表达。结果肿瘤组织中MMP-2、MMP-9、Cathepsin-D的阳性率分别为56·7%(153/270)、59·6%(161/270)、55·6%(150/270);单因素分析MMP-2阳性、MMP-9阳性及两者共表达患者有较低的无复发生存率,多因素分析发现MMP-2和MMP-9共表达能独立预测患者的无复发生存率(RR=2·487;P<0·05)。结论在淋巴结阴性乳腺癌患者中MMP-2和MMP-9的阳性表达患者的预后较差。
Objective To investigate the relationship between the expression of MMP-2, MMP-9 and Cathepsin-D in lymph node-negative breast cancer and its prognosis. Methods The expression of MMP-2, MMP-9 and Cathepsin-D in 270 patients with lymph node-negative breast cancer was detected by immunohistochemical ABC method. Results The positive rates of MMP-2, MMP-9 and Cathepsin-D in the tumor tissues were 56.7% (153/270), 59.6% (161/270) and 55.6% (150/270) respectively. Univariate analysis showed that the co-expression of MMP-2, MMP-9 and their co-expression had a low relapse-free survival rate. Multivariate analysis showed that the co-expression of MMP-2 and MMP-9 independently predicted the recurrence-free survival RR = 2.487; P <0.05). Conclusion The prognosis of patients with positive expression of MMP-2 and MMP-9 in patients with lymph node-negative breast cancer is poor.